The European experience with conducting health technology assessments demonstrates the limitations of current approaches to comparative effectiveness, according to Biogen Inc. VP EU+ Market Access and Pricing Chris Leibman.
That could inform the way US payers approach valuing orphan drugs for reimbursement decisions, Leibman suggested at the Institute for...






